IWWM-11 2022 | Ibrutinib therapy for Waldenström’s macroglobulinemia: real-world experiences in the UK
Shirley D’Sa
• 29 Oct 2022
Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, highlights real-world experiences with the use of ibrutinib for the treatment of patients with Waldenström’s macroglobulinemia (WM) in the UK. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards
